| scholarly article | Q13442814 |
| P50 | author | Daria Mochly-Rosen | Q56073232 |
| P2093 | author name string | Julio C B Ferreira | |
| P2860 | cites work | An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation | Q24535741 |
| Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart | Q24656840 | ||
| Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant | Q27658903 | ||
| A short history of nitroglycerine and nitric oxide in pharmacology and physiology | Q28142777 | ||
| Inhibition of NADPH-cytochrome P450 reductase and glyceryl trinitrate biotransformation by diphenyleneiodonium sulfate | Q28569170 | ||
| 4-Hydroxynonenal regulates 26S proteasomal degradation of alcohol dehydrogenase. | Q30343662 | ||
| Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations | Q30449094 | ||
| Role of disulfiram in the in vitro inhibition of rat liver mitochondrial aldehyde dehydrogenase | Q31438086 | ||
| Aldehyde dehydrogenase 2 in cardiac protection: a new therapeutic target? | Q33797190 | ||
| After 130 years, the molecular mechanism of action of nitroglycerin is revealed | Q34029878 | ||
| Identification of the enzymatic mechanism of nitroglycerin bioactivation | Q34032459 | ||
| Disruption of the coenzyme binding site and dimer interface revealed in the crystal structure of mitochondrial aldehyde dehydrogenase "Asian" variant | Q34093072 | ||
| Mitochondrial aldehyde dehydrogenase and cardiac diseases | Q34113383 | ||
| ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice g | Q34154695 | ||
| Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. | Q34312771 | ||
| Beneficial actions of nitrates in cardiovascular disease | Q34380794 | ||
| Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism | Q71010232 | ||
| Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates | Q72488009 | ||
| Effects of organic nitrates on mitochondrial respiration and swelling: possible correlations with the mechanism of pharmacologic action | Q72765719 | ||
| Reactions of nitric oxide with cytochrome c oxidase | Q72874971 | ||
| Mechanism for the inhibition of aldehyde dehydrogenase by nitric oxide | Q73188022 | ||
| Inhibition of platelet aggregation with glyceryl trinitrate and xanthine oxidoreductase | Q73289554 | ||
| Alcohol and cancer | Q73968013 | ||
| Preventive effects of angiotensin-converting enzyme inhibitors on nitrate tolerance during continuous transdermal application of nitroglycerin in patients with chronic heart failure | Q74648628 | ||
| Nitrite reductase activity is a novel function of mammalian mitochondria | Q78020403 | ||
| Nitrate tolerance in hypertension: new insight into a century-old problem | Q79237337 | ||
| Complex I dysfunction and tolerance to nitroglycerin: an approach based on mitochondrial-targeted antioxidants | Q79278862 | ||
| Long-term nitrate therapy after acute myocardial infarction does not improve or aggravate prognosis | Q79831284 | ||
| Bioactivation of nitroglycerin by ascorbate | Q80186654 | ||
| ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the M | Q34649834 | ||
| PKCβII inhibition attenuates myocardial infarction induced heart failure and is associated with a reduction of fibrosis and pro-inflammatory responses | Q35106609 | ||
| Reactions of 4-hydroxynonenal with proteins and cellular targets | Q35874119 | ||
| Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance | Q35996876 | ||
| Explaining the phenomenon of nitrate tolerance | Q36272905 | ||
| ALDH2 activator inhibits increased myocardial infarction injury by nitroglycerin tolerance | Q36541250 | ||
| Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase | Q36630533 | ||
| Nitrate-induced toxicity and preconditioning: a rationale for reconsidering the use of these drugs. | Q37219154 | ||
| Mitochondrial aldehyde dehydrogenase (ALDH-2)--maker of and marker for nitrate tolerance in response to nitroglycerin treatment | Q37286410 | ||
| Bioactivation of organic nitrates and the mechanism of nitrate tolerance. | Q37364642 | ||
| Nitrate tolerance as a model of vascular dysfunction: roles for mitochondrial aldehyde dehydrogenase and mitochondrial oxidative stress | Q37421153 | ||
| Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein | Q38274417 | ||
| Guanylate cyclase: activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin | Q38807815 | ||
| Comparison of Placebo, Nitroglycerin, and Isosorbide Dinitrate for Effectiveness of Relief of Angina and Duration of Action | Q39577149 | ||
| Hemodynamic effects of nitroglycerin and long-acting nitrates | Q39847741 | ||
| Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. | Q40483773 | ||
| Contribution of aldehyde dehydrogenase to mitochondrial bioactivation of nitroglycerin: evidence for the activation of purified soluble guanylate cyclase through direct formation of nitric oxide. | Q40514133 | ||
| Cytochrome P-450 mediates bioactivation of organic nitrates | Q41617006 | ||
| Characterization of the East Asian variant of aldehyde dehydrogenase-2: bioactivation of nitroglycerin and effects of Alda-1. | Q41965258 | ||
| Regulation of mitochondrial processes: a target for heart failure | Q42102232 | ||
| Heterozygous deficiency of manganese superoxide dismutase in mice (Mn-SOD+/-): a novel approach to assess the role of oxidative stress for the development of nitrate tolerance | Q42479234 | ||
| Role of the general base Glu-268 in nitroglycerin bioactivation and superoxide formation by aldehyde dehydrogenase-2. | Q42550000 | ||
| Coadministration of carvedilol attenuates nitrate tolerance by preventing cytochrome p450 depletion | Q43007209 | ||
| Sulfhydryl requirement for relaxation of vascular smooth muscle | Q43474382 | ||
| Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. | Q43594098 | ||
| Effect of long-term nitrate treatment on cardiac events in patients with vasospastic angina | Q43648485 | ||
| Aldehyde dehydrogenase 2 gene is a risk factor for myocardial infarction in Japanese men. | Q44229504 | ||
| Epidemiologic study of the association of low-Km mitochondrial acetaldehyde dehydrogenase genotypes with blood pressure level and the prevalence of hypertension in a general population | Q44250881 | ||
| Genetic deficiency of a mitochondrial aldehyde dehydrogenase increases serum lipid peroxides in community-dwelling females | Q44540942 | ||
| Aldehyde dehydrogenase, nitric oxide synthase and superoxide in ex vivo nitrate tolerance in rat aorta. | Q45003388 | ||
| Role of mitochondrial aldehyde dehydrogenase in nitroglycerin-induced vasodilation of coronary and systemic vessels: an intact canine model | Q45004060 | ||
| Exercise training reduces cardiac angiotensin II levels and prevents cardiac dysfunction in a genetic model of sympathetic hyperactivity-induced heart failure in mice. | Q45348628 | ||
| Mitochondrial nitrite reduction coupled to soluble guanylate cyclase activation: lack of evidence for a role in the bioactivation of nitroglycerin. | Q45755999 | ||
| Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans | Q46624700 | ||
| Glutathione S-transferase-mediated metabolism of glyceryl trinitrate in subcellular fractions of bovine coronary arteries | Q46692859 | ||
| Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure | Q46804727 | ||
| Oxidative inhibition of the mitochondrial aldehyde dehydrogenase promotes nitroglycerin tolerance in human blood vessels | Q46864918 | ||
| A Glu487Lys polymorphism in the gene for mitochondrial aldehyde dehydrogenase 2 is associated with myocardial infarction in elderly Korean men. | Q53572279 | ||
| Nitrates as adjunct hypertensive treatment: a possible answer to resistant systolic hypertension. | Q53871640 | ||
| Isosorbide dinitrate in acute and chronic heart failure | Q54574466 | ||
| Effect of nitroglycerin on the coronary circulation in patients with coronary artery disease or increased left ventricular work. | Q55037272 | ||
| Purification and characterization of glutathione transferases with an activity toward nitroglycerin from human aorta and heart. Multiplicity of the human class Mu forms | Q67287251 | ||
| Antagonism of glycerol trinitrate activity by an inhibitor of glutathione S-transferase | Q69207838 | ||
| P433 | issue | 1 | |
| P921 | main subject | myocardial infarction | Q12152 |
| nitroglycerin | Q162867 | ||
| P304 | page(s) | 15-21 | |
| P577 | publication date | 2011-11-01 | |
| P1433 | published in | Circulation Journal | Q1955928 |
| P1476 | title | Nitroglycerin use in myocardial infarction patients | |
| P478 | volume | 76 |
| Q35619842 | A personalized medicine approach for Asian Americans with the aldehyde dehydrogenase 2*2 variant |
| Q34137983 | Aldehyde dehydrogenase 2 activation in heart failure restores mitochondrial function and improves ventricular function and remodelling. |
| Q35510238 | Aldehydic load and aldehyde dehydrogenase 2 profile during the progression of post-myocardial infarction cardiomyopathy: benefits of Alda-1 |
| Q61519185 | Cardioprotection induced by a brief exposure to acetaldehyde: role of aldehyde dehydrogenase 2 |
| Q30596680 | Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphism using a human induced pluripotent stem cell model system |
| Q39017060 | Disruption of mitochondrial quality control in peripheral artery disease: New therapeutic opportunities |
| Q36798068 | Educational Case: A 57-year-old man with chest pain. |
| Q46782572 | Enhancement on reactive oxygen species and COX-1 mRNA levels modulate the vascular relaxation induced by sodium nitroprusside in denuded mice aorta |
| Q36941158 | In vivo reduction of cell-free methemoglobin to oxyhemoglobin results in vasoconstriction in canines |
| Q39994155 | Increased clearance of reactive aldehydes and damaged proteins in hypertension-induced compensated cardiac hypertrophy: impact of exercise training. |
| Q28072801 | Mitochondrial Quality Control in Cardiac Diseases |
| Q41089202 | Mitochondrial aldehyde dehydrogenase 2 accentuates aging-induced cardiac remodeling and contractile dysfunction: role of AMPK, Sirt1, and mitochondrial function |
| Q38132341 | Mitochondrial autophagy--an essential quality control mechanism for myocardial homeostasis |
| Q47669705 | NO and HNO donors, nitrones, and nitroxides: Past, present, and future |
| Q52354401 | Role of Non-Myocyte Gap Junctions and Connexin Hemichannels in Cardiovascular Health and Disease: Novel Therapeutic Targets? |
| Q47988079 | Systemic glyceryl trinitrate reduces anal sphincter tone: is there a therapeutic indication? |
| Q34395219 | Targeting aldehyde dehydrogenase 2: new therapeutic opportunities |
Search more.